Influence of pertussis toxine on local progression and metastasis after orthotopic implantation of the human prostate cancer cell line PC3 in nude mice

被引:14
作者
Bex, A
Lümmen, G
Rembrink, K
Otto, T
Metz, K
Rübben, H
机构
[1] Univ Essen Gesamthsch, Sch Med, Urol Clin, D-45122 Essen, Germany
[2] Univ Essen Gesamthsch, Sch Med, Inst Pathol, D-45122 Essen, Germany
关键词
prostate cancer; metastasis; experimental animal; antimotility factor;
D O I
10.1038/sj.pcan.4500286
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor cell migration is a fundamental process of metastasis. Pertussis toxine inhibits lysophosphatidic acid related cell migration by ADP-ribosylation of G proteins. We examined the influence of pertussis toxine (PTX) on progression and metastasis of the human hormone-insensitive prostate cancer cell line PC-3 after orthotopic implantation in nude mice. In 30 athymic male nude mice (NMRI) 5 x 10(5) PC-3 cells were injected into the dorsal prostate. After 7d 15 mice received a total of six intraperitoneal injections of 5 mu g PTX/100 g body weight at an interval of 4 d. The other 15 mice received phosphate buffered saline and served as control. All mice were killed at 37 d followed by macroscopical and histological evaluation of local tumor growth and metastasis. In the control group tumorigenicity was 100%; (15 out of 15). Mean weight of the tumor bearing unit of prostate and seminal vesicles was 541mg (243-763 mg). The rate of positive lymphnodes was 100% with a mean transversal diameter of 3.9 mm (1.2-5.4 mm). In the PTX group local take rate was 100% with a mean weight of 251mg (88-478 mg) (P two sided <0.0001). The rate of positive lymphnodes was 60% (9 out of 15) (P = 0.017) with a mean transversal diameter of 2.3 mm (1.0-4.5 mm). PTX following orthotopic implantation of the human hormone-insensitive PC-3 cell line significantly reduces local tumor growth as well as metastasis to locoregional lymphnodes.
引用
收藏
页码:36 / 40
页数:5
相关论文
共 24 条
  • [1] BEX A, 1998, AKTUEL UROL, V28, P43
  • [2] CANCER STATISTICS, 1994
    BORING, CC
    SQUIRES, TS
    TONG, T
    MONTGOMERY, S
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 1994, 44 (01) : 7 - 26
  • [3] CHEN Q, 1998, J CELL PHYSL, V174, P261
  • [4] CHUNG LWK, 1992, J CELL BIOCHEM, P99
  • [5] SECRETION OF EPIDERMAL GROWTH-FACTOR AND RELATED POLYPEPTIDES BY THE DU-145 HUMAN-PROSTATE CANCER CELL-LINE
    CONNOLLY, JM
    ROSE, DP
    [J]. PROSTATE, 1989, 15 (02) : 177 - 186
  • [6] Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
    Eisenberger, MA
    Blumenstein, BA
    Crawford, ED
    Miller, G
    McLeod, DG
    Loehrer, PJ
    Wilding, G
    Sears, K
    Culkin, DJ
    Thompson, IM
    Bueschen, AJ
    Lowe, BA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (15) : 1036 - 1042
  • [7] EFFECT OF EPIDERMAL GROWTH-FACTOR ON PROSTATE-CANCER CELL-LINE PC3 GROWTH AND INVASION
    JARRARD, DF
    BLITZ, BF
    SMITH, RC
    PATAI, BL
    RUKSTALIS, DB
    [J]. PROSTATE, 1994, 24 (01) : 46 - 53
  • [8] KAIGHN ME, 1979, INVEST UROL, V17, P16
  • [9] ANDROGEN RECEPTOR ALTERATIONS IN PROSTATIC-CARCINOMA
    KLOCKER, H
    CULIG, Z
    HOBISCH, A
    CATO, ACB
    BARTSCH, G
    [J]. PROSTATE, 1994, 25 (05) : 266 - 273
  • [10] Liotta L A, 1991, Semin Cancer Biol, V2, P111